LS-associated UTUC cases often exhibit germline mutations in the MSH2 gene, with rates ranging from 63% to 100%, involving 77% of ureteral cancers and 74% of renal pelvis cancers (18). This evidence concerns the gene MSH2 and renal pelvis/ureter urothelial carcinoma.